Abstract

Background

TCF is one of the most effective first-line options in metastatic GEC. We previously reported the significant activity of mTCF-dd (Tomasello G et al: Gastric Cancer 2014 Oct;17(4):711-7). Aim of this study is to describe clinical outcomes, safety and studying potential clinical prognostic factors of this intensified regimen in a very large consecutive cohort of pts coming from a single center

Methods

201 consecutive pts with measurable or evaluable GEC treated in the same